A Study Of BRL49653C For The Treatment Of Type 2 Diabetes
NCT00523913 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 70
Last updated 2016-10-28
Summary
This study is designed to evaluate the safety of BRL49653C administrated for 52 weeks
Conditions
- Diabetes Mellitus, Type 2
Interventions
- DRUG
-
rosiglitazone
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
GSK Clinical Trials · GlaxoSmithKline
Study Design
- Allocation
- NON_RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 20 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2005-11-30
- Completion
- 2007-04-30
Countries
More Related Trials
-
Efficacy and Safety of Treatment With Balaglitazone in Type 2 Diabetes Patients on Stable Insulin Therapy
NCT00515632 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Evaluate the Efficacy and Safety of BRL 49653C in Non-insulin Dependent Diabetes
NCT01706211 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy and Safety Study of Rosiglitazone/Metformin Therapy vs Rosiglitazone and Metformin in Type 2 Diabetes Subjects
NCT00499707 ·Status: COMPLETED ·Phase: PHASE3
-
Malignancy Meta Analysis for BRL49653
NCT01195259 ·Status: COMPLETED
-
A Study To Evaluate The Safety And Efficacy Of An Investigational Diabetes Drug In Poorly Controlled Type II Diabetics
NCT00067951 ·Status: COMPLETED ·Phase: PHASE3
-
Rosiglitazone to Reverse Metabolic Defects in Diabetes
NCT00094796 ·Status: COMPLETED ·Phase: PHASE2
-
Efficacy and Safety In Poorly Controlled Type 2 Diabetics
NCT00044460 ·Status: COMPLETED ·Phase: PHASE4
-
RECORD: Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycaemia in Diabetes
NCT00379769 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy and Safety of HRS9531 in Participants With Type 2 Diabetes Treated With Basal Insulin
NCT07060456 ·Status: RECRUITING ·Phase: PHASE3
-
A Study of GZR18 Injection in Chinese Adult Patients With Type 2 Diabetes Mellitus (T2DM)
NCT06256523 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Safety and Pharmacokinetics Study of XOMA 052 in Subjects With Type 2 Diabetes Mellitus
NCT00513214 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Effects of Rosiglitazone on Plasma BNP Levels and Left Ventricular Dysfunction
NCT00300911 ·Status: COMPLETED ·Phase: PHASE4
-
A Study of ZT002 Injection in Adult Chinese Subjects With Type 2 Diabetes Mellitus (T2DM)
NCT07065032 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RZ-629 in Healthy Subjects and T2D
NCT06829563 ·Status: RECRUITING ·Phase: PHASE1
-
Single, Ascending Dose, First Time in Human Study for GZR18 in Healthy Subjects
NCT05328726 ·Status: COMPLETED ·Phase: PHASE1
-
Ambulatory Blood Pressure Reduction After Rosiglitazone Treatment In Normotensive Type 2 Diabetic Patients
NCT00290394 ·Status: COMPLETED ·Phase: PHASE4
-
Efficacy and Safety of HRS9531 Injection in Type 2 Diabetes Subjects
NCT05966272 ·Status: COMPLETED ·Phase: PHASE2
-
Placebo Controlled Dose-Response Study of Rivoglitazone in Type 2 Diabetes
NCT00575471 ·Status: COMPLETED ·Phase: PHASE2
-
Rosiglitazone-Metformin Combination Versus Metformin-Sulfonylurea Combination On Beta-Cell Function In Type 2 Diabetes
NCT00367055 ·Status: COMPLETED ·Phase: PHASE4
-
Investigation of Vascular Relaxing Effects of the Antidiabetic Rosiglitazone.
NCT00154011 ·Status: COMPLETED ·Phase: NA
-
Rosiglitazone and Exercise in Patients With Type 2 Diabetes Mellitus
NCT00306176 ·Status: COMPLETED ·Phase: PHASE4
-
Effect of Rosiglitazone on Myocardial Blood Flow Regulation in Type 2 Diabetes
NCT00549874 ·Status: COMPLETED ·Phase: NA
-
Efficacy and Safety of SHR-3167 and Insulin Glargine in Type 2 Diabetes Subjects
NCT06688123 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
A Study of ZT002 in Healthy Participants
NCT05491421 ·Status: COMPLETED ·Phase: PHASE1
-
A Study With RO5095932 in Patients With Type 2 Diabetes on Stable Metformin Therapy.
NCT01017302 ·Status: COMPLETED ·Phase: PHASE1